Return-to-Office Pushes Can Cause a ‘Riot’
Copyright Clearance Center
JANUARY 23, 2024
A growing number of managers want workers in the office more often, citing the connections, collaborations, and innovations that in-person work can bring.
January, 2024
136 
Pfizer's layoff campaign ramps back up with dozens of SF-area cuts expected next month
Fierce Pharma
JANUARY 29, 2024
The start of the new year doesn’t seem to have dulled the zeal of Pfizer’s global cost-cutting campaign, which has already left hundreds of jobs in its wake. | Come mid-February, Pfizer will lay off some 52 employees at a facility in South San Francisco, according to a recent Worker Adjustment and Retraining Notification Act alert. The site is the former headquarters of Global Blood Therapeutics.
Pharma Horizons: Artificial Intelligence
European Pharmaceutical Review
JANUARY 24, 2024
The first in our inaugural Pharma Horizons report series is dedicated to exploring the latest advances in artificial intelligence (AI) and machine learning (ML) for drug development, pharmaceutical manufacturing and quality control. AI/ML is predicted to be the top technology investment for 60 percent of life sciences companies over the next two years, according to a recent survey 1 from the Pistoia Alliance.
Merck is on the lookout for more opportunities within immunology
Pharmaceutical Technology
JANUARY 29, 2024
At the JP Morgan Healthcare conference, Merck (MSD) indicated its eagerness to continue to establish its place in the immunological space.
5 Ways You Can Win Faster with Gen AI in Sales
Advertiser: ZoomInfo
Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.
We’ve Actually Treated Tens of Thousands of People on Ozempic to Date – Here’s What Really Happens and What It Likely Means for Solving Our Obesity Epidemic
MedCity News
JANUARY 31, 2024
We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.
Novartis calls time on Tim3 drug sabatolimab in MDS
pharmaphorum
JANUARY 31, 2024
Novartis ends development of Tim3 antibody sabatolimab in myelodysplastic syndromes after failed phase 3 trial.
Sign up to get articles personalized to your interests!
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
More Trending
Millions of doses of Pfizer's Paxlovid will go to waste in UK, EU as COVID demand plummets
Fierce Pharma
JANUARY 2, 2024
On the heels of a major Paxlovid inventory write-off in the United States, many more doses of Pfizer's COVID-fighting antiviral are going to waste overseas. | At the end of November, more than 1.5 million courses of Pfizer’s Paxlovid had expired unused in European countries, analysts at Airfinity said in a new report. The total tally of expired doses in Europe is expected to hit 3.1 million by the end of next month, representing a value of $2.2 billion.
Charting a course for ongoing omnichannel excellence
Dominic Tyer
JANUARY 30, 2024
Successful customer engagement will require pharma companies to maintain a rigid focus throughout the journey
STOP SETTLING: How Playing it Safe is Killing Your Medical Rep Career in 2024
Medical Sales Guru
JANUARY 2, 2024
The role of a medical sales representative involves navigating intricate dynamics with healthcare professionals. These professionals hold significant authority in determining a salesperson’s access and the fate of a product. Consequently, many representatives opt to play it safe , fearing potential alienation that might hinder future sales opportunities.
Ex-Pfizer Employee Convicted for Insider Trades Ahead of Positive Paxlovid Data
MedCity News
JANUARY 19, 2024
The former Pfizer statistician worked on the clinical trial for the Covid-19 drug Paxlovid. A jury found the employee guilty of insider trading for transactions made before clinical data for the antiviral were publicly announced.
AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
CG Oncology is first biotech IPO of 2024, raising $380m
pharmaphorum
JANUARY 24, 2024
CG Oncology completes the first biotech IPO of 2024, raising $380 million for its oncolytic virus bladder cancer immunotherapy.
How Quantum Computing Will Impact Pharma in 2024: Q&A With Erik Huestis, Partner at Foley Hoag
PharmExec
JANUARY 8, 2024
Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.
Former Pfizer statistician found guilty of insider trading on Paxlovid trial results
Fierce Pharma
JANUARY 19, 2024
A jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in federal court in the Southern District of New York. | A federal jury has found a former Pfizer statistician guilty of insider trading after a two-week trial in Manhattan. The jury convicted Amit Dagar, 44, of Hillsborough, N.J., of using advance information on successful trial results for Pfizer’s COVID-19 treatment Paxlovid to make more than $270,000 in stock trades.
Transforming pharmaceutical manufacturing: The AI revolution
European Pharmaceutical Review
JANUARY 9, 2024
Revolutionising quality control In the backdrop of stringent quality standards and regulatory demands inherent to pharmaceutical manufacturing, the addition of AI technologies introduce a paradigm shift. This article highlights the manifold applications of AI, particularly cutting-edge image recognition and computer vision systems, which profoundly impact quality control.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
AbbVie and Umoja to develop new CAR-T therapies for cancer
Pharmaceutical Technology
JANUARY 5, 2024
AbbVie and Umoja Biopharma partnered for the development of in-situ CAR-T cell therapy candidates for oncology targets.
Deloitte: 7 Trends Shaping Healthcare and Life Sciences in 2024
MedCity News
JANUARY 19, 2024
AI, health equity and merger and acquisition activity are among the trends to watch in 2024, according to a recent report from Deloitte.
Risk model predicts response and survival of cancer patients treated with ICIs
PharmaTimes
JANUARY 4, 2024
Metastatic cancer is estimated to be responsible for 90% of cancer deaths
MHRA’s post-Brexit mutual recognition framework goes live
pharmaphorum
JANUARY 3, 2024
The UK medicines regulator has launched its mutual recognition framework for authorising medicines in a move that it says will help to bring new drugs to patients in the UK more quickly.
Novo Nordisk, Eli Lilly's weight-loss drugs under FDA scrutiny for suicidal thoughts, hair loss
Fierce Pharma
JANUARY 4, 2024
Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus, which can be life threatening. | Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus. Could cautions about more common side effects soon be added to the labels of popular treatments such as Novo’s Ozempic and Lilly’s Mounjaro?
Will new therapeutic agent replace antibodies for bacterial detection?
European Pharmaceutical Review
JANUARY 23, 2024
As a tool for detecting and identifying bacteria, aptamers are a promising new class of synthetic nucleic acid molecules that can be used to detect and treat of pathogenic bacteria. With the ability to be developed against a whole bacterium, a microbial toxin, or some proteins, for some bacteria, “aptamers against pathogens can not only supplement the deficiency of antibodies but can also enrich the aptamer database to develop efficient analytical regents”, according to a paper published in the
Expert analysis: the latest in HIV research and clinical trials
Pharmaceutical Technology
JANUARY 3, 2024
A new report from Novotech delves into the multifaceted landscape of HIV, focusing on its impact, treatment, and global initiatives.
How Digital Health Fundraising Took On a Different Shape in 2023
MedCity News
JANUARY 10, 2024
In 2023, digital health fundraising took on a bit of a different shape, according to a new Rock Health report. Startups tried out some creative ways to keep their businesses afloat — including series extension rounds, unlabeled fundraises and silent deals from existing investors.
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Researchers identify gene that causes heart defects in Down syndrome
PharmaTimes
JANUARY 25, 2024
Around 50% of babies born with the condition are affected by heart defects
Adverse Event Reports Linked to Counterfeit Ozempic on the Rise
Pharmaceutical Commerce
JANUARY 26, 2024
Concerns regarding hypoglycemia potentially linked to a counterfeit version of Ozempic come at a time in which reports have grown regarding the improper use of GLP-1 receptor agonists for the purpose of cosmetic weight loss.
Merck's Keytruda extends life for kidney cancer patients after surgery, while Bristol's Opdivo fails again
Fierce Pharma
JANUARY 26, 2024
Merck’s unique approval for Keytruda as a postsurgical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can extend patients’ lives. | Merck’s unique approval for Keytruda as a postsurgerical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can extend patients’ lives.
Collaboration to develop novel AI-designed oncology therapy
European Pharmaceutical Review
JANUARY 5, 2024
Under a new licensing agreement, Stemline Therapeutics, Inc., a wholly-owned subsidiary of the Menarini Group, gains the global rights to develop and commercialise a novel, small molecule KAT6A inhibitor. This treatment has potential for hormone sensitive cancers such as breast cancer, and other oncology indications. The therapeutic is designed using the artificial intelligence (AI)-platform from Insilico Medicine, the biotech company that is also part of this collaboration.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Merck, Johnson & Johnson Announce Acquisitions to Bolster Respective Oncology Pipelines
PharmExec
JANUARY 9, 2024
Merck has acquired Harpoon Therapeutics with its clinical stage T-cell engager, whereas Johnson & Johnson acquired Ambrx Biopharma with its expertise in next generation antibody drug conjugates and targeted oncologic therapies.
‘Food Equity Can’t Be a Side Gig’: How Food as Medicine is Becoming A Core Team Capability
MedCity News
JANUARY 28, 2024
As the food as medicine movement grows, some payers and healthcare organizations are carving out specific roles and teams dedicated to food and nutrition. Doing so can be beneficial considering the significant impact diet can have on health outcomes.
International consortium identifies biomarkers for cardiovascular disease in diabetes
PharmaTimes
JANUARY 30, 2024
Type 2 diabetes is estimated to affect 462 million people worldwide
New Web of Science Grants Index helps researchers develop more targeted grant proposals
Clarivate
JANUARY 28, 2024
Competition for funding is tough and researchers need help to make their grant applications stand out. The Web of Science Grants Index from Clarivate helps researchers seamlessly incorporate valuable awarded grant data from hundreds of funders into their grant proposal development. By exploring what has already been funded, researchers can make informed decisions when applying for new grants.
10 Ways to Leverage Buyer Signals and Drive Revenue
Advertiser: ZoomInfo
In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.
Let's personalize your content